Last reviewed · How we verify
Vastarel (TRIMETAZIDINE)
Trimetazidine works by optimizing the heart's energy production, reducing the amount of oxygen required by the heart muscle.
Vastarel, also known as Trimetazidine, is a small molecule drug in the trimetazidine class. It is used to treat Angina pectoris, a condition characterized by chest pain due to reduced blood flow to the heart. The commercial status of Vastarel is not specified, but it is likely patented. Key safety considerations include unknown half-life, bioavailability, and potential side effects. As a treatment for Angina pectoris, Vastarel is likely to be used in patients with a history of heart disease.
At a glance
| Generic name | TRIMETAZIDINE |
|---|---|
| Drug class | trimetazidine |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | discontinued |
Mechanism of action
Imagine your heart as a car engine. Trimetazidine helps the engine run more efficiently, using less fuel (oxygen) to produce the same amount of power. This reduces the strain on the heart and helps alleviate symptoms of Angina pectoris.
Approved indications
- Angina pectoris
Common side effects
- Cardiac failure
- Rales
- Stenosis
- Dyspnoea at rest
- Ejection fraction decreased
- Diastolic dysfunction
- Tricuspid valve incompetence
- Angina pectoris
- Pulmonary valve disease
- Pericardial disease
- Hepatic vein dilatation
- Acute myocardial infarction
Key clinical trials
- Effect of Long Term Trimetazidine Treatment on Final Myocardial Fibrosis for ST Eleviation Myocardial Infarction
- Modifiable Risk Factors for Non-traumatic Subconjunctival Hemorrhage
- Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients (PHASE3)
- Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI (PHASE4)
- "The Effect of Trimetazidine on the Clinical Outcome of Acute Ischemic Stroke Patients" (PHASE3)
- Metoprolol and Trimetazidine for Coronary Heart Disease With Angina (NA)
- Benefits of Trimetazidine in MASLD Patients (PHASE2)
- Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vastarel CI brief — competitive landscape report
- Vastarel updates RSS · CI watch RSS